ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2918 • 2018 ACR/ARHP Annual Meeting

    Physical Activity in Canadian Children with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

    Lori Tucker1, Jaime Guzman1, Kristin Houghton2, Dax G. Rumsey3, Elizabeth Stringer4, Shirley M.L. Tse5, Rosie Scuccimarri6, Claire LeBlanc7, Roberta Berard8, Bianca Lang9, Karen N Watanabe Duffy10 and Ciarán M. Duffy11, 1BC Children's Hospital, Vancouver, BC, Canada, 2Rheumatology/Pediatrics, British Columbia Children's Hospital, Vancouver, BC, Canada, 3Stollery Children's Hospital, Edmonton, AB, Canada, 4Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Department of Pediatrics, McGill University Health Centre, Montreal, QC, Canada, 7Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada, 8Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, 9Pediatrics, IWK Health Centre, Halifax, NS, Canada, 10Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 11Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Physical activity (PA) is an important component of health, and is essential for optimal growth and development. Children with juvenile idiopathic arthritis (JIA) are…
  • Abstract Number: 2919 • 2018 ACR/ARHP Annual Meeting

    An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors

    Shima Yasin1, Christopher Towe2,3, Ndate Fall4, Alexei Grom3,4 and Grant Schulert1,5, 1Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pulmonology, Division of Pulmonology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 4Division of Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Pediatrics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: There is growing awareness of severe and often fatal chronic lung disease in patients with systemic juvenile idiopathic arthritis (sJIA). However, clinical features and…
  • Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting

    Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis

    Gian Marco Moneta1, Ivan Caiello1, Lucilla Rava'2, Silvia Rosina3, Luisa Bracci Laudiero1,4, Angelo Ravelli3,5, Fabrizio De Benedetti6 and Rebecca Nicolai7, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 3University of Genova, Genova, Italy, 4Institute of Translational Pharmacology, CNR, Roma, Italy, 5Rheumatology, Giannina Gaslini Institute, Genova, Italy, 6IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 7Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

    Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
  • Abstract Number: 2921 • 2018 ACR/ARHP Annual Meeting

    The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus

    Sezgin Sahin1, Sule Bektas1, Amra Adrovic1, Oya Koker2, Kenan Barut1 and Ozgur Kasapcopur3, 1Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey

    Background/Purpose: To avoid misclassifications, a new set of classification criteria have been developed by the collaboration of the EULAR/ACR and the draft was presented at…
  • Abstract Number: 2922 • 2018 ACR/ARHP Annual Meeting

    Magnetic Resonance Imaging of Sacroiliac Joints in Patients with Osteitis Condensans Ilii Reveals a Typical Pattern of Lesions Relevant for Differential Diagnosis with Axial Spondyloarthritis

    Denis Poddubnyy1,2, Torsten Diekhoff3, Nino Gobejishvili3, Henning Weineck3, Maria Llop Vilaltella3, Valeria Rios Rodriguez3, Joachim Sieper2 and Kay-Geert Hermann3, 1German Rheumatism Research Centre, Berlin, Germany, 2Charité Universitätsmeidzin Berlin, Berlin, Germany, 3Charité Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Osteitis condensans ilii (OCI) is regarded to as a non-inflammatory disorder induced by mechanical stress and mechanical instability of the sacroiliac joints (SIJ). OCI…
  • Abstract Number: 2923 • 2018 ACR/ARHP Annual Meeting

    Is All MRI-SIJ Inflammation the Same? Gradient of Structural Damage with Increasing Cumulative Inflammation at the SIJ Quadrant Level in Axial Spondyloarthritis – 5-Year Data from the DESIR Cohort

    Santiago Rodrigues Manica1,2, Alexandre Sepriano1,3, Sofia Ramiro3,4, Robert B.M. Landewé5, Pascal Claudepierre6, Anna Moltó7, Maxime Dougados8, Miranda van Lunteren3 and Désirée van der Heijde9, 1CEDOC, NOVA Medical School, Lisbon, Portugal, 2Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, Zuyderland Medical Center, Heerlen, Netherlands, 5Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, 6Hôpital Henri Mondor, Créteil, France, 7Paris Descartes University, Cochin Hospital, Paris, France, 8Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, 9Leiden University Medical Centre, Leiden, Netherlands

    Background/Purpose: Axial inflammation is a key feature in axial spondyloarthritis (axSpA). An (overall) definition of bone marrow oedema (BMO) on the MRI of the SIJ…
  • Abstract Number: 2924 • 2018 ACR/ARHP Annual Meeting

    Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort

    Sofia Ramiro1, Désirée van der Heijde2, Alexandre Sepriano3, Miranda van Lunteren4, Anna Molto5, Maria Antonietta D'Agostino6, Damien Loeuille7, Maxime Dougados8, M. Reijnierse9 and Pascal Claudepierre10, 1Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, 6Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, 7Rheumatology, University Hospital of Nancy, NANCY, France, 8Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, 9Radiology, Leiden University Medical Center, Leiden, Netherlands, 10Hôpital Henri Mondor, Créteil, France

    Background/Purpose: Spinal radiographic progression has been investigated in patients with r-axSpA, but not yet as thoroughly in early axSpA. We aimed to analyse the progression…
  • Abstract Number: 2925 • 2018 ACR/ARHP Annual Meeting

    Fatty Lesions Detected on MRI Scans in Patients with Ankylosing Spondylitis Are Based on the Deposition of Fat in the Vertebral Bone Marrow

    Xenofon Baraliakos1, Heinrich Boehm2, Ahmed Samir3, Georg Schett4, Jürgen Braun5 and Andreas Ramming6, 1Ruhr-University Bochum, Herne, Germany, 2Clinic for spinal surgery, Bad Berka, Germany, 3Orthopedic and Traumatology Department, Cairo University, Cairo, Egypt, 4Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, 5Ruhr Universität Bochum, Bochum, Germany, 6Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Fatty lesions (FL), similar to bone marrow edema (BME) and sclerosis (SCL), are characteristic findings in MRI examinations of patients with ankylosing spondylitis (AS)…
  • Abstract Number: 2926 • 2018 ACR/ARHP Annual Meeting

    Which MRI Lesions in the Sacroiliac Joint Are Associated with the Diagnosis of Axial Spondyloarthritis after 2 Years Follow up in the Echography in Spondyloarthritis Cohort?

    Walter P. Maksymowych1,2, Damien Loeuille3, Stephanie Wichuk4, Joel Paschke5, Olivia Judet6, Maxime Breban3, Maria-Antonietta D'Agostino7 and Robert G. Lambert8, 1University of Alberta, Edmonton, AB, Canada, 2CaRE Arthritis, Edmonton, AB, Canada, 3Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, 5CaRE Arthritis, Edmonton, Canada, Edmonton, AB, Canada, 6CHRU Vandoeuvre les Nancy, Vandœuvre-lès-Nancy, France, 7CHRU Vandoeuvre les Nancy, Vandoeuvre les Nancy, France, 8Radiology, Radiology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: MRI of the sacroiliac joint (SIJ) is emerging as an important prognostic tool for assessment of patients presenting with axSpA. A major challenge in…
  • Abstract Number: 2927 • 2018 ACR/ARHP Annual Meeting

    What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers?

    Walter P. Maksymowych1,2, Pedro Machado3, Ulrich Weber4, Xenofon Baraliakos5, Joachim Sieper6, Stephanie Wichuk1, Denis Poddubnyy6, Mikkel Østergaard7, Joel Paschke2, Robert G. Lambert1 and Susanne J Pedersen7, 1University of Alberta, Edmonton, AB, Canada, 2CaRE Arthritis, Edmonton, AB, Canada, 3University College London, London, United Kingdom, 4University of Southern Denmark, Odense, Denmark, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Charité Universitätsmeidzin Berlin, Berlin, Germany, 7COPECARE University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Defining what constitutes a definite MRI lesion in the SIJ typical of axSpA has been hampered by lack of international consensus for standardized lesion…
  • Abstract Number: 2928 • 2018 ACR/ARHP Annual Meeting

    Validation of New Systemic Lupus Erythematosus Classification Criteria

    Martin Aringer1, Karen Costenbader2, Ralph Brinks3, Dimitrios Boumpas4, David Daikh5, David Jayne6, Diane L. Kamen7, Marta Mosca8, Rosalind Ramsey-Goldman9, Josef S. Smolen10, David Wofsy11, Betty Diamond12, Søren Jacobsen13, W. Joseph McCune14, Guillermo Ruiz-Irastorza15, Matthias Schneider16, Murray Urowitz17, George Bertsias18, Bimba Hoyer19, Nicolai Leuchten1, Chiara Tani20, Sara K. Tedeschi21, Zahi Touma22, Branimir Anic23, Florence Assan24, Tak Mao Chan25, Ann E. Clarke26, Peggy Crow27, László Czirják28, Andrea Doria29, Winfried Graninger30, Bernadett Halda-Kiss28, Sarfaraz A. Hasni31, Peter M. Izmirly32, Michelle Jung33, Gabor Kumanovics28, Xavier Mariette24, Ivan Padjen23, JM Pego-Reigosa34, Juanita Romero-Díaz35, Iñigo Rúa-Figueroa36, Raphaele Seror37, Georg Stummvoll38, Yoshiya Tanaka39, Maria Tektonidou40, Carlos Vasconcelos41, Edward M Vital42, Daniel J. Wallace43, Sule Yavuz44, Raymond P. Naden45, Thomas Dörner46 and Sindhu Johnson47, 1Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2Rheumatology, Immunology and All, Brigham & Women's Hospital, Boston, MA, 3Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, 4University of Athens, Athens, Greece, 5Rheumatology, UCSF and VA Medical Center, San Francisco, CA, 6Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 7Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 8Rheumatology Unit, University of Pisa, Pisa, Italy, 9FSM, Northwestern University, Chicago, IL, 10Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 11University of California San Francisco, San Francisco, CA, 12Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, 13University of Copenhagen, Copenhagen, Denmark, 14Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 15Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain, 16Department and Hiller Research Center for Rheumatology, Heinrich-Heine University, Duesseldorf, Germany, 17University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, 18Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, 19University of Schleswig-Holstein, Kiel, Germany, 20University of Pisa, Pisa, Italy, 21Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, 22University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 23Department of Internal Medicine, University Hospital Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, 24Université Paris Sud, Paris, France, 25University of Hong Kong, Hong Kong, Hong Kong, 26Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 27Department of Medicine, Hospital for Special Surgery, New York, NY, 28Rheumatology and Immunology, University of Pécs, Pécs, Hungary, 29University and Azienda Ospedaliera of Padova, Padova, Italy, 30Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 31Lupus Clinical Research Program, Office of the Clinical Director, NIH/NIAMS, Bethesda, MD, 32NYU Langone Health, New York, NY, 33University of Calgary, Calgary, AB, Canada, 34Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 35Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 36Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, 37Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, 38Rheumatology, Medical University Vienna, Vienna, Austria, 39University of Occupational and Environmental Health, Kitakyushu, Japan, 40Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece, 41Centro Hospitalar do Porto, University of Porto, Porto, Portugal, 42University of Leeds, Leeds, United Kingdom, 43Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 44Department of Rheumatology, Marmara University, Istanbul, Turkey, 45New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, 46Charité Universitätsmedizin Berlin, Berlin, Germany, 47Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

    Background/Purpose: Correct classification of patients with systemic lupus erythematosus (SLE) is critical for clinical trials and clinical and translational science. The ACR 1997 criteria were…
  • Abstract Number: 2929 • 2018 ACR/ARHP Annual Meeting

    Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE

    Michelle Petri1, Daniel Goldman1 and Laurence S Magder2, 1Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, 2Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
  • Abstract Number: 2930 • 2018 ACR/ARHP Annual Meeting

    Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus

    Vera Golder1, Rangi Kandane-Rathnayake2, Molla Huq3, Worawit Louthrenoo4, Shue-Fen Luo5, Yeong-Jian Wu6, Aisha Lateef7, Sargunan Sockalingam8, Susan Morton9, Sandra V. Navarra10, Leonid Zamora11, Laniyati Hamijoyo12, Yasuhiro Katsumata13, Masayoshi Harigai14, Madelynn Chan15, Sean O'Neill16, Fiona Goldblatt17, Chak Sing Lau18, Zhan-Guo Li19, Alberta Y. Hoi2, Mandana Nikpour20 and Eric Morand21, 1School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 4Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 5Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 6Chang Gung University, Taoyuan County, Taiwan, 7Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, 8University of Malaya, Kuala Lumpur, Malaysia, 9Monash Health, Melbourne, Australia, 10University of Santo Tomas Hospital, Manila, Philippines, 11Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 12University of Padjadjaran, Bandung, Indonesia, 13Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 14Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, 15Tan Tock Seng Hospital, Singapore, Singapore, 16University of New South Wales, Sydney, Australia, 17Royal Adelaide Hospital, Adelaide, Australia, 18Medicine, The University of Hong Kong, Hong Kong, Hong Kong, 19Rheum/Immunology, Peking University People's Hospital, Beijing, China, 20The University of Melbourne, Melbourne, Australia, Melbourne, Australia, 21Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not previously been…
  • Abstract Number: 2931 • 2018 ACR/ARHP Annual Meeting

    Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects

    Mimi Kim1, Joan T. Merrill2, Kenneth C. Kalunian3, Leslie Hanrahan4 and Peter M. Izmirly5, 1Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4Lupus Foundation of America, Washington DC, DC, 5NYU Langone Health, New York, NY

    Background/Purpose:  Missing data due to drop-out and loss to follow-up is a common problem in SLE trials. The usual approaches for handling this issue include…
  • Abstract Number: 2932 • 2018 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology

    Eric Grund1, Lixia Zhang1, Leonardo Rodrigues1, Viatcheslav Akmaev1, Rangaprasad Sarangarajan1, Michael Kiebish1, Niven Narain1 and Gary S. Gilkeson2, 1BERG, LLC, Framingham, MA, 2Department of Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Biomarkers for use in developing treatments and diagnostics for Systemic Lupus Erythematosus (SLE) are a large unmet need. The wide differential in patient progression…
  • « Previous Page
  • 1
  • …
  • 1197
  • 1198
  • 1199
  • 1200
  • 1201
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology